Tag: Elexacaftor

Traditionally, cystic fibrosis (CF) has been managed with treatments that address symptoms rather than the underlying cause. The emergence of Trikafta has revolutionized this approach, providing a targeted therapy that directly addresses the defective protein, significantly improving lung function and overall health for many with CF.

More than 90% of cystic fibrosis (CF) patients in the United States are eligible for treatment with Trikafta. So, what class of drug is Trikafta? It belongs to a revolutionary class of medications known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators, specifically a triple-combination therapy, that directly targets the underlying genetic cause of the disease.